FAES Farma SA - Product Pipeline Review - 2015

Date: May 13, 2015
Pages: 27
Price:
US$ 1,500.00 US$ 1,200.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: F0427ED5FB7EN
Leaflet:

Download PDF Leaflet

FAES Farma SA - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘FAES Farma SA - Product Pipeline Review - 2015’, provides an overview of the FAES Farma SA’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of FAES Farma SA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of FAES Farma SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of FAES Farma SA’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the FAES Farma SA’s pipeline products
Reasons to buy
  • Evaluate FAES Farma SA’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of FAES Farma SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the FAES Farma SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of FAES Farma SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of FAES Farma SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of FAES Farma SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
FAES Farma SA Snapshot
FAES Farma SA Overview
Key Information
Key Facts
FAES Farma SA - Research and Development Overview
Key Therapeutic Areas
FAES Farma SA - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
FAES Farma SA - Pipeline Products Glance
FAES Farma SA - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
FAES Farma SA - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
FAES Farma SA - Drug Profiles
bilastine
Product Description
Mechanism of Action
R&D Progress
Drugs for Dermatitis
Product Description
Mechanism of Action
R&D Progress
Drugs for Immunology
Product Description
Mechanism of Action
R&D Progress

F-10503LO1

Product Description
Mechanism of Action
R&D Progress

F-98214TA

Product Description
Mechanism of Action
R&D Progress
FAES Farma SA - Pipeline Analysis
FAES Farma SA - Pipeline Products by Target
FAES Farma SA - Pipeline Products by Route of Administration
FAES Farma SA - Pipeline Products by Molecule Type
FAES Farma SA - Pipeline Products by Mechanism of Action
FAES Farma SA - Recent Pipeline Updates
FAES Farma SA - Dormant Projects
FAES Farma SA - Company Statement
FAES Farma SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

FAES Farma SA, Key Information
FAES Farma SA, Key Facts
FAES Farma SA - Pipeline by Indication, 2015
FAES Farma SA - Pipeline by Stage of Development, 2015
FAES Farma SA - Monotherapy Products in Pipeline, 2015
FAES Farma SA - Phase III, 2015
FAES Farma SA - Preclinical, 2015
FAES Farma SA - Pipeline by Target, 2015
FAES Farma SA - Pipeline by Route of Administration, 2015
FAES Farma SA - Pipeline by Molecule Type, 2015
FAES Farma SA - Pipeline Products by Mechanism of Action, 2015
FAES Farma SA - Recent Pipeline Updates, 2015
FAES Farma SA - Dormant Developmental Projects,2015
FAES Farma SA, Other Locations
FAES Farma SA, Subsidiaries

LIST OF FIGURES

FAES Farma SA - Pipeline by Top 10 Indication, 2015
FAES Farma SA - Pipeline by Stage of Development, 2015
FAES Farma SA - Monotherapy Products in Pipeline, 2015
FAES Farma SA - Pipeline by Top 10 Target, 2015
FAES Farma SA - Pipeline by Top 10 Molecule Type, 2015
FAES Farma SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


Paralysis - Pipeline Review, H1 2015 US$ 1,600.00 Mar, 2015 · 45 pages
Lanthio Pharma B.V. - Product Pipeline Review - 2014 US$ 1,125.00 Jul, 2014 · 22 pages
Nyken BV - Product Pipeline Review - 2014 US$ 1,125.00 Jun, 2014 · 21 pages

Ask Your Question

FAES Farma SA - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: